Author: van Zuylen, Wendy J.; Doyon, Priscilla; Clément, Jean-François; Khan, Kashif Aziz; D'Ambrosio, Lisa M.; Dô, Florence; St-Amant-Verret, Myriam; Wissanji, Tasheen; Emery, Gregory; Gingras, Anne-Claude; Meloche, Sylvain; Servant, Marc J.
Title: Proteomic Profiling of the TRAF3 Interactome Network Reveals a New Role for the ER-to-Golgi Transport Compartments in Innate Immunity Document date: 2012_7_5
ID: 1m5dbwjv_21
Snippet: Next we examined the effect of reducing the expression level of Sec16A or p115 on the ability of TRAF3 to colocalize with MAVS upon SeV infection. As expected, TRAF3 localization reorganized into punctate structures following SeV infection, allowing a significant proportion of TRAF3 to colocalize with MAVS ( Figure 6A , panel 2). This effect was severely compromised by reducing the expression of Sec16A or p115 ( Figure 6A , compare panels 4 and 6.....
Document: Next we examined the effect of reducing the expression level of Sec16A or p115 on the ability of TRAF3 to colocalize with MAVS upon SeV infection. As expected, TRAF3 localization reorganized into punctate structures following SeV infection, allowing a significant proportion of TRAF3 to colocalize with MAVS ( Figure 6A , panel 2). This effect was severely compromised by reducing the expression of Sec16A or p115 ( Figure 6A , compare panels 4 and 6 with panel 2). Additionally, co-immunoprecipitation experiments revealed that TRAF3 formed an immunocomplex with MAVS upon SeV infection. Interestingly, silencing the expression level of p115 or Sec16A clearly blunted the ability of TRAF3 to bind to MAVS upon SeV infection ( Figures 6B and 6C ). Thus loss-of-function experiments targeting p115 and Sec16A led to a mislocalization of TRAF3 and its subsequent incapacity to associate with MAVS upon RLH pathway activation.
Search related documents:
Co phrase search for related documents- expression level and MAVS associate: 1
- expression level and pathway activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- expression level and RLH pathway activation: 1
- expression level and sev infection: 1, 2
- function loss and pathway activation: 1, 2, 3
- function loss and sev infection: 1
- function loss and significant proportion: 1, 2, 3, 4
- MAVS associate and pathway activation: 1, 2
- MAVS associate and RLH pathway activation: 1, 2
- MAVS associate and sev infection: 1
- MAVS colocalize and pathway activation: 1
- MAVS colocalize and RLH pathway activation: 1
- pathway activation and RLH pathway activation: 1, 2
- pathway activation and sev infection: 1, 2, 3
- pathway activation and significant proportion: 1
- RLH pathway activation and sev infection: 1
Co phrase search for related documents, hyperlinks ordered by date